CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: chronic hepatitis B</title> <meta name="description" content="Search results for: chronic hepatitis B"> <meta name="keywords" content="chronic hepatitis B"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="chronic hepatitis B" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="chronic hepatitis B"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 1475</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: chronic hepatitis B</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1475</span> Dynamic Modelling of Hepatitis B Patient Using Sihar Model</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Alakija%20Temitope%20Olufunmilayo">Alakija Temitope Olufunmilayo</a>, <a href="https://publications.waset.org/abstracts/search?q=Akinyemi"> Akinyemi</a>, <a href="https://publications.waset.org/abstracts/search?q=Yagba%20Joy"> Yagba Joy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis is the inflammation of the liver tissue that can cause whiteness of the eyes (Jaundice), lack of appetite, vomiting, tiredness, abdominal pain, diarrhea. Hepatitis is acute if it resolves within 6 months and chronic if it last longer than 6 months. Acute hepatitis can resolve on its own, lead to chronic hepatitis or rarely result in acute liver failure. Chronic hepatitis may lead to scarring of the liver (Cirrhosis), liver failure and liver cancer. Modelling Hepatitis B may become necessary in order to reduce its spread. So, dynamic SIR model can be used. This model consists of a system of three coupled non-linear ordinary differential equation which does not have an explicit formula solution. It is an epidemiological model used to predict the dynamics of infectious disease by categorizing the population into three possible compartments. In this study, a five-compartment dynamic model of Hepatitis B disease was proposed and developed by adding control measure of sensitizing the public called awareness. All the mathematical and statistical formulation of the model, especially the general equilibrium of the model, was derived, including the nonlinear least square estimators. The initial parameters of the model were derived using nonlinear least square embedded in R code. The result study shows that the proportion of Hepatitis B patient in the study population is 1.4 per 1,000,000 populations. The estimated Hepatitis B induced death rate is 0.0108, meaning that 1.08% of the infected individuals die of the disease. The reproduction number of Hepatitis B diseases in Nigeria is 6.0, meaning that one individual can infect more than 6.0 people. The effect of sensitizing the public on the basic reproduction number is significant as the reproduction number is reduced. The study therefore recommends that programme should be designed by government and non-governmental organization to sensitize the entire Nigeria population in order to reduce cases of Hepatitis B disease among the citizens. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title="hepatitis B">hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=modelling" title=" modelling"> modelling</a>, <a href="https://publications.waset.org/abstracts/search?q=non-linear%20ordinary%20differential%20equation" title=" non-linear ordinary differential equation"> non-linear ordinary differential equation</a>, <a href="https://publications.waset.org/abstracts/search?q=sihar%20model" title=" sihar model"> sihar model</a>, <a href="https://publications.waset.org/abstracts/search?q=sensitization" title=" sensitization"> sensitization</a> </p> <a href="https://publications.waset.org/abstracts/171002/dynamic-modelling-of-hepatitis-b-patient-using-sihar-model" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/171002.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">89</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1474</span> Still Hepatocellular Carcinoma Risk Despite Proper Treatment of Chronic Viral Hepatitis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sila%20Akhan">Sila Akhan</a>, <a href="https://publications.waset.org/abstracts/search?q=Muge%20Toygar"> Muge Toygar</a>, <a href="https://publications.waset.org/abstracts/search?q=Murat%20Sayan"> Murat Sayan</a>, <a href="https://publications.waset.org/abstracts/search?q=Simge%20Fidan"> Simge Fidan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Chronic viral hepatitis B, C, and D can cause hepatocellular carcinoma (HCC), cirrhosis and death. The proper treatment reduce the risk of development of HCC importantly, but not to zero point. Materials and Methods: We analysed retrospectively our chronic viral hepatitis B, C and D patients who attended to our Infectious Diseases policlinic between 2004-2018. From 589 biopsy-proven chronic hepatitis patients 3 have hepatocellular carcinoma on our follow up. First case is 74 years old patient. His HCV infection diagnosis was made 8 years ago. First treatment was pegylated interferon plus ribavirin only 28 weeks, because of HCV RNA breakthrough under treatment. In 2013 he was retreated with telaprevir, pegylated interferon plus ribavirin 24 weeks. But at the end of the therapy HCV RNA was found 1.290.000 IU/mL. He has abdominal ultrasonography (US) controls and alpha-fetoprotein (AFP) at 6 months intervals. All seemed normal until 2015 then he has an abdominal magnetic resonance imaging (MRI) and found HCC by chance. His treatment began in Oncology Clinic after verified with biopsy of HCC. And then sofosbuvir/ledipasvir was given to him for HCV 24 weeks. Sustained virologic response (SVR) was obtained. He is on cure for HCV infection and under control of Oncology for HCC. Second patient is 36 years old man. He knows his HBV infection since 2008. HBsAg and HBeAg positive; HDV RNA negative. Liver biopsy revealed grade:4, stage 3-4 according modified Knodell scoring system. In 2010 tenofovir treatment was began. His abdominal US and AFP were normal. His controls took place at 6 months intervals and HBV DNA negative, US, and AFP were normal until 2016 continuously. AFP found 37 above the normal range and then HCC was found in MRI. Third patient is 57 years old man. As hepatitis B infection was first diagnosed; he has cirrhosis and was began tenofovir as treatment. In short time he has HCC despite normal AFP values. Conclusion: In Mediterranian countries including Turkey naturally occurring pre-S/S variants are more than 75% of all chronic hepatitis B patients. This variants may contribute to the development of progressive liver damage and hepatocarcinogenesis. HCV-induced development of HCC is a gradual process and is affected by the duration of disease and viral genotype. All the chronic viral hepatitis patients should be followed up in 6 months intervals not only with US and AFP for HCC. Despite they have proper treatment there is always the risk development of HCC. Chronic hepatitis patients cannot be dropped from follow up even treated well. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HCC" title="HCC">HCC</a>, <a href="https://publications.waset.org/abstracts/search?q=HCV" title=" HCV"> HCV</a>, <a href="https://publications.waset.org/abstracts/search?q=HBV" title=" HBV"> HBV</a>, <a href="https://publications.waset.org/abstracts/search?q=DAA" title=" DAA"> DAA</a> </p> <a href="https://publications.waset.org/abstracts/94789/still-hepatocellular-carcinoma-risk-despite-proper-treatment-of-chronic-viral-hepatitis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/94789.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">137</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1473</span> A Case Study of Response to Dual Genotype Chronic Hepatitis C/HIV Co-Infection to Fixed Dose Sofosbuvir/Ledipasvir</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tabassum%20Yasmin">Tabassum Yasmin</a>, <a href="https://publications.waset.org/abstracts/search?q=Hamid%20Pahlevan"> Hamid Pahlevan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> HIV/Hepatitis C co-infection treatments have evolved substantially and they have similar sustained virologic response rates as those of Hepatitis C monoinfected population. There are a few studies on therapy of patients with dual genotypes, especially in HIV/Hepatic C coinfected group. Most studies portrayed case reports of dual genotype chronic Hepatitis C coinfection treatment with Sofosbuvir/Ledipasvir and Ribavirin. A 79-year-old male with a history of HIV on Truvada and Isentress had chronic Hepatitis C with 1a and 2 genotypes. The patient has a history of alcohol intake for 40 years but recently stopped drinking alcohol. He has a history of intravenous drug use in the past and currently is not using any recreational drugs. Patient has Fibro score of 0.7 with Metavir score F2 to F4. AFP is 3.2. The HCV RNA is 493,034 IU/ML. The HBV viral DNA is < 1.30 (not detected). The CD4 is 687CU/MM. The FIB 4 is 3.34 with APRI index 0.717. The HIV viral load is 101 copies/ML. MRI abdomen did not show any liver abnormality. Fixed dose Sofosbuvir/Ledipasvir was used for therapy without Ribavirin. He tolerated medication except for some minor gastrointestinal side effects like abdominal bloating. He demonstrated 100% adherence rate. Patient completed 12 weeks of therapy. HCV RNA was undetectable at 4 and 12 weeks. He achieved SVR at week 12 and subsequently had undetectable RNA for 2 years. Dual genotype prevalence in chronic hepatitis C population is rare, especially in HIV/hepatic coinfection. Our case demonstrates that dual genotypic cases can still be successfully treated with Direct Acting Antiviral agents. The newer agents for therapy for pan genotypes were not available at the time the patient was being treated. We demonstrated that dual agent therapy was still able to maintain SVR in our patient. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HIV%2FHepatitis%20C" title="HIV/Hepatitis C">HIV/Hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=SVR%20%28sustained%20virologic%20response%29" title=" SVR (sustained virologic response)"> SVR (sustained virologic response)</a>, <a href="https://publications.waset.org/abstracts/search?q=DAA%20%28direct%20active%20antiviral%20agents" title=" DAA (direct active antiviral agents"> DAA (direct active antiviral agents</a>, <a href="https://publications.waset.org/abstracts/search?q=dual%20genotype" title=" dual genotype"> dual genotype</a> </p> <a href="https://publications.waset.org/abstracts/77565/a-case-study-of-response-to-dual-genotype-chronic-hepatitis-chiv-co-infection-to-fixed-dose-sofosbuvirledipasvir" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/77565.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">196</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1472</span> Insulin Resistance in Patients with Chronic Hepatitis C Virus Infection: Upper Egypt Experience</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ali%20Kassem">Ali Kassem</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: In the last few years, factors such as insulin resistance (IR) and hepatic steatosis have been linked to progression of hepatic fibrosis.Patients with chronic liver disease, and cirrhosis in particular, are known to be prone to IR. However, chronic HCV (hepatitis C) infection may induce IR, regardless of the presence of liver cirrhosis. Our aims are to study insulin resistance (IR) assessed by HOMA-IR (Homeostatic Model Assessment Insulin Resistance) as a possible risk factor in disease progression in cirrhotic patients and to evaluate the role of IR in hepatic fibrosis progression. The correlations of HOMA-IR values to laboratory, virological and histopathological parameters of chronic HCV are also examined. Methods: The study included 50 people divided into 30 adult chronic hepatitis C patients diagnosed by PCR (polymerase chain reaction) within previous 6 months and 20 healthy controls. The functional and morphological status of the liver were evaluated by ultrasonography and laboratory investigations including liver function tests and by liver biopsy. Fasting blood glucose and fasting insulin levels were measured and body mass index and insulin resistance were calculated. Patients having HOMA-IR >2.5 were labeled as insulin resistant. Results: Chronic hepatitis C patients with IR showed significantly higher mean values of BMI (body mass index) and fasting insulin than those without IR (P < 0.000). Patients with IR were more likely to have steatosis (p = 0.006), higher necroinflammatory activity (p = 0.05). No significant differences were found between the two groups regarding hepatic fibrosis. Conclusion: HOMA-IR measurement could represent a novel marker to identify the cirrhotic patients at greater risk for the progression of liver disease. As IR is a potentially modifiable risk factor, these findings may have important prognostic and therapeutic implications. Assessment of IR by HOMA-IR and improving insulin sensitivity are recommended in patients with HCV and related chronic liver disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatic%20fibrosis" title="hepatic fibrosis">hepatic fibrosis</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20C%20virus%20infection" title=" hepatitis C virus infection"> hepatitis C virus infection</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatic%20steatosis" title=" hepatic steatosis"> hepatic steatosis</a>, <a href="https://publications.waset.org/abstracts/search?q=insulin%20resistance" title=" insulin resistance"> insulin resistance</a> </p> <a href="https://publications.waset.org/abstracts/94698/insulin-resistance-in-patients-with-chronic-hepatitis-c-virus-infection-upper-egypt-experience" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/94698.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">154</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1471</span> Comparison between Transient Elastography (FibroScan) and Liver Biopsy for Diagnosis of Hepatic Fibrosis in Chronic Hepatitis C Genotype 4</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Gamal%20Shiha">Gamal Shiha</a>, <a href="https://publications.waset.org/abstracts/search?q=Seham%20Seif"> Seham Seif</a>, <a href="https://publications.waset.org/abstracts/search?q=Shahera%20Etreby"> Shahera Etreby</a>, <a href="https://publications.waset.org/abstracts/search?q=Khaled%20Zalata"> Khaled Zalata</a>, <a href="https://publications.waset.org/abstracts/search?q=Waleed%20Samir"> Waleed Samir</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Transient Elastography (TE; FibroScan®) is a non-invasive technique to assess liver fibrosis. Aim: To compare TE and liver biopsy in hepatitis C virus (HCV) patients, genotype IV and evaluate the effect of steatosis and schistosomiasis on FibroScan. Methods: The fibrosis stage (METAVIR Score) TE, was assessed in 519 patients. The diagnostic performance of FibroScan is assessed by calculating the area under the receiver operating characteristic curves (AUROCs). Results: The cut-off value of ≥ F2 was 8.55 kPa, ≥ F3 was 10.2 kPa and cirrhosis = F4 was 16.3 kPa. The positive predictive value and negative predictive value were 70.1% and 81.7% for the diagnosis of ≥ F2, 62.6% and 96.22% for F ≥ 3, and 27.7% and 100% for F4. No significant difference between schistosomiasis, steatosis degree and FibroScan measurements. Conclusion: Fibroscan could accurately predict liver fibrosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20C" title="chronic hepatitis C">chronic hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=FibroScan" title=" FibroScan"> FibroScan</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20biopsy" title=" liver biopsy"> liver biopsy</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20fibrosis" title=" liver fibrosis"> liver fibrosis</a> </p> <a href="https://publications.waset.org/abstracts/3662/comparison-between-transient-elastography-fibroscan-and-liver-biopsy-for-diagnosis-of-hepatic-fibrosis-in-chronic-hepatitis-c-genotype-4" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/3662.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">409</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1470</span> Evaluation of the Hepatitis C Virus and Classical and Modern Immunoassays Used Nowadays to Diagnose It in Tirana</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Stela%20Papa">Stela Papa</a>, <a href="https://publications.waset.org/abstracts/search?q=Klementina%20Puto"> Klementina Puto</a>, <a href="https://publications.waset.org/abstracts/search?q=Migena%20Pllaha"> Migena Pllaha</a> </p> <p class="card-text"><strong>Abstract:</strong></p> HCV is a hepatotropic RNA virus, transmitted primarily via the blood route, which causes progressive disease such as chronic hepatitis, liver cirrhosis, or hepatocellular carcinoma. HCV nowadays is a global healthcare problem. A variety of immunoassays including old and new technologies are being applied to detect HCV in our country. These methods include Immunochromatography assays (ICA), Fluorescence immunoassay (FIA), Enzyme linked fluorescent assay (ELFA), and Enzyme linked immunosorbent assay (ELISA) to detect HCV antibodies in blood serum, which lately is being slowly replaced by more sensitive methods such as rapid automated analyzer chemiluminescence immunoassay (CLIA). The aim of this study is to estimate HCV infection in carriers and chronic acute patients and to evaluate the use of new diagnostic methods. This study was realized from September 2016 to May 2018. During this study period, 2913 patients were analyzed for the presence of HCV by taking samples from their blood serum. The immunoassays performed were ICA, FIA, ELFA, ELISA, and CLIA assays. Concluding, 82% of patients taken in this study, resulted infected with HCV. Diagnostic methods in clinical laboratories are crucial in the early stages of infection, in the management of chronic hepatitis and in the treatment of patients during their disease. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=CLIA" title="CLIA">CLIA</a>, <a href="https://publications.waset.org/abstracts/search?q=ELISA" title=" ELISA"> ELISA</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C%20virus" title=" Hepatitis C virus"> Hepatitis C virus</a>, <a href="https://publications.waset.org/abstracts/search?q=immunoassay" title=" immunoassay"> immunoassay</a> </p> <a href="https://publications.waset.org/abstracts/110783/evaluation-of-the-hepatitis-c-virus-and-classical-and-modern-immunoassays-used-nowadays-to-diagnose-it-in-tirana" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/110783.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">153</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1469</span> Prospective Validation of the FibroTest Score in Assessing Liver Fibrosis in Hepatitis C Infection with Genotype 4</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=G.%20Shiha">G. Shiha</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Seif"> S. Seif</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20Samir"> W. Samir</a>, <a href="https://publications.waset.org/abstracts/search?q=K.%20Zalata"> K. Zalata</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Prospective Validation of the FibroTest Score in assessing Liver Fibrosis in Hepatitis C Infection with Genotype 4 FibroTest (FT) is non-invasive score of liver fibrosis that combines the quantitative results of 5 serum biochemical markers (alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma glutamyl transpeptidase (GGT) and bilirubin) and adjusted with the patient's age and sex in a patented algorithm to generate a measure of fibrosis. FT has been validated in patients with chronic hepatitis C (CHC) (Halfon et al., Gastroenterol. Clin Biol.( 2008), 32 6suppl 1, 22-39). The validation of fibro test ( FT) in genotype IV is not well studied. Our aim was to evaluate the performance of FibroTest in an independent prospective cohort of hepatitis C patients with genotype 4. Subject was 122 patients with CHC. All liver biopsies were scored using METAVIR system. Our fibrosis score(FT) were measured, and the performance of the cut-off score were done using ROC curve. Among patients with advanced fibrosis, the FT was identically matched with the liver biopsy in 18.6%, overestimated the stage of fibrosis in 44.2% and underestimated the stage of fibrosis in 37.7% of cases. Also in patients with no/mild fibrosis, identical matching was detected in 39.2% of cases with overestimation in 48.1% and underestimation in 12.7%. So, the overall results of the test were identical matching, overestimation and underestimation in 32%, 46.7% and 21.3% respectively. Using ROC curve it was found that (FT) at the cut-off point of 0.555 could discriminate early from advanced stages of fibrosis with an area under ROC curve (AUC) of 0.72, sensitivity of 65%, specificity of 69%, PPV of 68%, NPV of 66% and accuracy of 67%. As FibroTest Score overestimates the stage of advanced fibrosis, it should not be considered as a reliable surrogate for liver biopsy in hepatitis C infection with genotype 4. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=fibrotest" title="fibrotest">fibrotest</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20Hepatitis%20C" title=" chronic Hepatitis C"> chronic Hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=genotype%204" title=" genotype 4"> genotype 4</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20biopsy" title=" liver biopsy"> liver biopsy</a> </p> <a href="https://publications.waset.org/abstracts/4304/prospective-validation-of-the-fibrotest-score-in-assessing-liver-fibrosis-in-hepatitis-c-infection-with-genotype-4" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/4304.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">414</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1468</span> Predictive Value of Hepatitis B Core-Related Antigen (HBcrAg) during Natural History of Hepatitis B Virus Infection</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yanhua%20Zhao">Yanhua Zhao</a>, <a href="https://publications.waset.org/abstracts/search?q=Yu%20Gou"> Yu Gou</a>, <a href="https://publications.waset.org/abstracts/search?q=Shu%20Feng"> Shu Feng</a>, <a href="https://publications.waset.org/abstracts/search?q=Dongdong%20Li"> Dongdong Li</a>, <a href="https://publications.waset.org/abstracts/search?q=Chuanmin%20Tao"> Chuanmin Tao</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The natural history of HBV infection could experience immune tolerant (IT), immune clearance (IC), HBeAg-negative inactive/quienscent carrier (ENQ), and HBeAg-negative hepatitis (ENH). As current biomarkers for discriminating these four phases have some weaknesses, additional serological indicators are needed. Hepatits B core-related antigen (HBcrAg) encoded with precore/core gene contains denatured HBeAg, HBV core antigen (HBcAg) and a 22KDa precore protein (p22cr), which was demonstrated to have a close association with natural history of hepatitis B infection, but no specific cutoff values and diagnostic parameters to evaluate the diagnostic efficacy. This study aimed to clarify the distribution of HBcrAg levels and evaluate its diagnostic performance during the natural history of infection from a Western Chinese perspective. 294 samples collected from treatment-naïve chronic hepatitis B (CHB) patients in different phases (IT=64; IC=72; ENQ=100, and ENH=58). We detected the HBcrAg values and analyzed the relationship between HBcrAg and HBV DNA. HBsAg and other clinical parameters were quantitatively tested. HBcrAg levels of four phases were 9.30 log U/mL, 8.80 log U/mL, 3.00 log U/mL, and 5.10 logU/mL, respectively (p < 0.0001). Receiver operating characteristic curve analysis demonstrated that the area under curves (AUCs) of HBcrAg and quantitative HBsAg at cutoff values of 9.25 log U/mL and 4.355 log IU/mL for distinguishing IT from IC phases were 0.704 and 0.694, with sensitivity 76.39% and 59.72%, specificity 53.13% and 79.69%, respectively. AUCs of HBcrAg and quantitative HBsAg at cutoff values of 4.15 log U/mlmL and 2.395 log IU/mlmL for discriminating between ENQ and ENH phases were 0.931 and 0.653, with sensitivity 87.93% and 84%, specificity 91.38% and 39%, respectively. Therefore, HBcrAg levels varied significantly among four natural phases of HBV infection. It had higher predictive performance than quantitative HBsAg for distinguishing between ENQ-patients and ENH-patients and similar performance with HBsAg for the discrimination between IT and IC phases, which indicated that HBcrAg could be a potential serological marker for CHB. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B" title="chronic hepatitis B">chronic hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20core-related%20antigen" title=" hepatitis B core-related antigen"> hepatitis B core-related antigen</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20surface%20antigens" title=" hepatitis B surface antigens"> hepatitis B surface antigens</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20virus" title=" hepatitis B virus"> hepatitis B virus</a> </p> <a href="https://publications.waset.org/abstracts/68938/predictive-value-of-hepatitis-b-core-related-antigen-hbcrag-during-natural-history-of-hepatitis-b-virus-infection" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/68938.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">417</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1467</span> Chronic Hepatitis C Virus Screening: The Role, Strategies and Challenging of Primary Healthcare Faced to Augment and Identify Asymptomatic Infected Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tarek%20K.%20Jalouta">Tarek K. Jalouta</a>, <a href="https://publications.waset.org/abstracts/search?q=Jolietta%20R.%20Holliman"> Jolietta R. Holliman</a>, <a href="https://publications.waset.org/abstracts/search?q=Kathryn%20R.%20Burke"> Kathryn R. Burke</a>, <a href="https://publications.waset.org/abstracts/search?q=Kathleen%20M.%20Bewley-Thomas"> Kathleen M. Bewley-Thomas</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Chronic hepatitis C virus (HCV) infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma. In the United States, HCV screening awareness, treatment, and linkage to care are under continues ascending progress. However, still millions of people are asymptomatically infected and undiagnosed yet. Through this community mission, we sought to identify the best and the newest strategies to identify those infected people to educate them, link them to care and cure them. Methods: We have identified patients that did not have a prior HCV screening in our Electronic medical record (EMR) including all our different hospital locations (South Suburban Chicago, Northern, Western and Central Indiana). Providing education to all Primary care/Gastroenterology/Infectious diseases providers and staff in the clinic to increase awareness of the HCV screening. Health-related quality of life, chronic clinical complications, and demographics data were collected for each patient. All outcomes of HCV antibody-reactive and HCV RNA–positive results were identified and statistically analyzed. Results: From July 2016 to July 2018 we screened 35,720 individuals of birth cohort in our different Franciscan’s health medical centers. Of the screened population, 986 (2.7%) individuals were HCV AB-reactive. Of those, 319 (1%) patients were HCV RNA-positive, and 264 patients were counseled and linked to providers. 34 patients initiated anti-HCV therapy with successful treatment. Conclusions: Our HCV screening augmentation project considered the largest screening program in the Midwest. Augmenting the HCV screening process through creating a Best Practice Alert (BPA) in the EMR (Epic Sys.) and point of care testing could be helpful. Although continued work is required, our team is working on increase screening through adding HCV test to CBC-Panels in Emergency Department settings, phone calls to all birth cohort individuals through Robo-Calling System aimed to reach 75,000 individuals by 2019. However, a better linkage to care and referral monitoring system to all HCV RNA positive patients is still needed, and access to therapy, especially for uninsured patients, is challenging. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20C" title="chronic hepatitis C">chronic hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20C%20treatment" title=" chronic hepatitis C treatment"> chronic hepatitis C treatment</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20C%20screening" title=" chronic hepatitis C screening"> chronic hepatitis C screening</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20C%20prevention" title=" chronic hepatitis C prevention"> chronic hepatitis C prevention</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20cancer" title=" liver cancer"> liver cancer</a> </p> <a href="https://publications.waset.org/abstracts/103853/chronic-hepatitis-c-virus-screening-the-role-strategies-and-challenging-of-primary-healthcare-faced-to-augment-and-identify-asymptomatic-infected-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/103853.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">125</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1466</span> Impact of Hepatitis C Virus Chronic Infection on Quality of Life in Egypt</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Ammal%20M.%20Metwally">Ammal M. Metwally</a>, <a href="https://publications.waset.org/abstracts/search?q=Ghada%20A.%20Abdel-Latif"> Ghada A. Abdel-Latif</a>, <a href="https://publications.waset.org/abstracts/search?q=Walaa%20A.%20Fouad"> Walaa A. Fouad</a>, <a href="https://publications.waset.org/abstracts/search?q=Thanaa%20M.%20Rabah"> Thanaa M. Rabah</a>, <a href="https://publications.waset.org/abstracts/search?q=Amira%20Mohsen"> Amira Mohsen</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatma%20A.%20Shaaban"> Fatma A. Shaaban</a>, <a href="https://publications.waset.org/abstracts/search?q=Iman%20I.%20Salama">Iman I. Salama</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The study aimed at determining the impact of chronic hepatitis C virus (HCV) infection on patients’ Quality of Life (QoL) , its relation to geographical characteristics of patients, awareness of the disease, treatment regimen, co-morbid psychiatric or other diseases. 457 patients were randomly selected from ten National Treatment Reference Centers of Ministry of Health hospitals from four community locations representing Egypt. Health related QoL assessment questionnaire with the 36-item Short Form used for assessment of the enrolled patients. The study showed no significant difference between HCV patients in different governorates as regards total QoL. Females, illiterate patients and those had bilharziasis, diabetes mellitus, hypertension or were depressed had significantly the lowest QoL score. HCV patients who knew the danger of the disease had significant lower mean score of physical and mental health components. Optimal care of overall well-being of HCV patients requires adequate knowledge of their neurological and psychological status. It is important to know that any patient will need to take the time to know that his new physical limitations do not limit him as a person, as soul, no matter what other people are thinking as a positive hopeful attitude is essential for combating HCV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20C%20virus%20chronic%20infection%20-%20physical%20health%20component%20and%20mental%20health%20component%20of%20QoL%E2%80%93%20total%20quality%20of%20life" title="hepatitis C virus chronic infection - physical health component and mental health component of QoL– total quality of life">hepatitis C virus chronic infection - physical health component and mental health component of QoL– total quality of life</a> </p> <a href="https://publications.waset.org/abstracts/3583/impact-of-hepatitis-c-virus-chronic-infection-on-quality-of-life-in-egypt" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/3583.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">449</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1465</span> MicroRNA Differential Profiling in Hepatitis C Patients Undergoing Major Surgeries: Propofol versus Sevoflurane Anesthesia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hala%20Demerdash">Hala Demerdash</a>, <a href="https://publications.waset.org/abstracts/search?q=Ola%20M.%20Zanaty"> Ola M. Zanaty</a>, <a href="https://publications.waset.org/abstracts/search?q=Emad%20Eldin%20Arida"> Emad Eldin Arida</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: This study investigated the micoRNA expression changes induced by Sevoflurane and Propofol and their effects on liver functions. Patients and methods: The study was designed as randomized controlled study, carried out on 200 adult patients, scheduled for major surgeries under general anesthesia (GA). Patients were randomly divided into four groups; groups SC and PC included chronic hepatitis C (CHC) patients where SC group are patients receiving Sevoflurane, and PC group are patients receiving Propofol anesthesia. While S and P groups included non- hepatitis patients; S group are patients receiving Sevoflurane and P group are patients receiving Propofol. Anesthesia in Group S and SC patients was maintained by sevoflurane, while anesthesia in Group P and PC patients was maintained by propofol infusion. Blood samples were analyzed for PT, PTT and liver enzymes. Serum samples were analyzed for microRNA before and after surgery. Results: Results show miRNA-122 and miRNA-21 were absent in serum of S and P groups in pre-operative samples. However, they were expressed in SC and PC groups. In post-operative samples; miRNA-122 revealed an increased expression in all groups; with more exaggerated response in SC group. On the other hand miRNA-21 revealed increased expression in both SC and PC groups; a slight expression in S group with absent expression in P group. There was a post-operative negative correlation between miR-122 and ALT (r=-0.46) in SC group and (r=-0.411) in PC group and positive correlation between ALT and miR-21 (r=0.335) in SC group and (r=0.379) in PC group. The amount of blood loss was positively correlated with miR-122 (r=0.366) in SC group and (r=0.384) in PC group. Conclusion: Propofol anesthesia is safer than Sevoflurane anesthesia in patients with CHC. Sevoflurane and Propofol anesthesia affect miRNA expression in both CHC and non-hepatitis patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anesthesia" title="anesthesia">anesthesia</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20C" title=" chronic hepatitis C"> chronic hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=micoRNA" title=" micoRNA"> micoRNA</a>, <a href="https://publications.waset.org/abstracts/search?q=propofol" title=" propofol"> propofol</a>, <a href="https://publications.waset.org/abstracts/search?q=sevoflurane" title=" sevoflurane"> sevoflurane</a> </p> <a href="https://publications.waset.org/abstracts/42677/microrna-differential-profiling-in-hepatitis-c-patients-undergoing-major-surgeries-propofol-versus-sevoflurane-anesthesia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/42677.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">341</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1464</span> Sero-Prevalence of Hepatitis B Surface Antigen and Associated Factors among Pregnant Mothers Attending Antenatal Care Service, Mekelle, Ethiopia: Evidence from Institutional Based Quantitative Cross-Sectional Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Semaw%20A.">Semaw A.</a>, <a href="https://publications.waset.org/abstracts/search?q=Awet%20H."> Awet H.</a>, <a href="https://publications.waset.org/abstracts/search?q=Yohannes%20M."> Yohannes M.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Hepatitis B Virus (HBV) is a major global public health problem. Individuals living in Sub-Sahara Africa have 60% lifetime risk of acquiring HBV infection. Evidences showed that 80-90% of those born from infected mothers developed chronic HBV. Perinatal HBV transmission is a major determinant of HBV carrier status, its chronic squeal and maintains HBV transmission across generations. Method: Institution based cross-sectional study was conducted among 406 pregnant mothers attending Antenatal clinics at Mekelle and Ayder referral hospital from January 30 to April 1/2014. Epidata version 3.1 was used for data entry and SPSS version 21 statistical software was used for data cleaning, management and finally determine associated factors of hepatitis B surface antigen adjusting important confounders using multivariable logistic regression analysis at 5% level of significance. Result: The overall prevalence of hepatitis B surface antigen among pregnant women was 33 (8.1%). The socio-demographic characteristic of the study population showed that there is high positivity among secondary school 189 (46.6%). In the multivariable logistic regression analysis, history of a contact with individuals who had history of hepatitis B infection or jaundice and lifetime number of multiple sexual partners were found to be significantly associated with HBsAg positivity at AOR = 3.73 95%C.I (1.373-10.182) and AOR = 2.57 95%C.I (1.173-5.654), respectively. Moreover, Human Immunodeficiency Virus (HIV) and HBV confection rate was found 3.6%. Conclusion: This study has shown that HBV prevalence in pregnant women is highly prevalent (8.1%) in the study area. Contact with individuals who had a history of hepatitis or have jaundice and report of multiple lifetime sexual partnership were associated with hepatitis B infection. Education about HBV transmission and prevention as well as screening all pregnant mothers shall be sought to reduce the serious public health crisis of HBV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HBsAg" title="HBsAg">HBsAg</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title=" hepatitis B"> hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=pregnant%20women" title=" pregnant women"> pregnant women</a>, <a href="https://publications.waset.org/abstracts/search?q=prevalence" title=" prevalence"> prevalence</a> </p> <a href="https://publications.waset.org/abstracts/34139/sero-prevalence-of-hepatitis-b-surface-antigen-and-associated-factors-among-pregnant-mothers-attending-antenatal-care-service-mekelle-ethiopia-evidence-from-institutional-based-quantitative-cross-sectional-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34139.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">340</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1463</span> Hepatitis B Vaccination Status and Its Determinants among Primary Health Care Workers in Northwest Pakistan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Tahir%20Yousafzai">Mohammad Tahir Yousafzai</a>, <a href="https://publications.waset.org/abstracts/search?q=Rubina%20Qasim"> Rubina Qasim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> We assessed Hepatitis B vaccination and its determinants among health care workers (HCW) in Northwest Pakistan. HCWs from both public and private clinics were interviewed about hepatitis B vaccination, socio-demographic, hepatitis B virus transmission modes, disease threat and benefits of vaccination. Logistic regression was performed. Hepatitis B vaccination was 40% (Qualified Physicians: 86% and non-qualified Dispensers:16%). Being Qualified Physician (Adj. OR 26.6; 95%CI 9.3-73.2), Non-qualified Physician (Adj.OR 1.9; 95%CI 0.8-4.6), qualified Dispensers (Adj. OR 3.6; 95%CI 1.3-9.5) compared to non-qualified Dispensers, working in public clinics (Adj. OR 2.5; 95%CI 1.1-5.7) compared to private, perceived disease threat after exposure to blood and body fluids (Adj. OR 1.1; 95%CI 1.1-1.2) and perceived benefits of vaccination (Adj. OR 1.1; 95%CI 1.1-1.2) were significant predictors of hepatitis B vaccination. Improved perception of disease threat and benefits of vaccination and qualification of HCWs are associated with hepatitis B vaccination. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B%20vaccine" title="Hepatitis B vaccine">Hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=immunization" title=" immunization"> immunization</a>, <a href="https://publications.waset.org/abstracts/search?q=healthcare%20workers" title=" healthcare workers"> healthcare workers</a>, <a href="https://publications.waset.org/abstracts/search?q=primary%20health" title=" primary health "> primary health </a> </p> <a href="https://publications.waset.org/abstracts/13926/hepatitis-b-vaccination-status-and-its-determinants-among-primary-health-care-workers-in-northwest-pakistan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/13926.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">314</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1462</span> Detection and Distribution Pattern of Prevelant Genotypes of Hepatitis C in a Tertiary Care Hospital of Western India </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Upasana%20Bhumbla">Upasana Bhumbla</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Hepatitis C virus is a major cause of chronic hepatitis, which can further lead to cirrhosis of the liver and hepatocellular carcinoma. Worldwide the burden of Hepatitis C infection has become a serious threat to the human race. Hepatitis C virus (HCV) has population-specific genotypes and provides valuable epidemiological and therapeutic information. Genotyping and assessment of viral load in HCV patients are important for planning the therapeutic strategies. The aim of the study is to study the changing trends of prevalence and genotypic distribution of hepatitis C virus in a tertiary care hospital in Western India. Methods: It is a retrospective study; blood samples were collected and tested for anti HCV antibodies by ELISA in Dept. of Microbiology. In seropositive Hepatitis C patients, quantification of HCV-RNA was done by real-time PCR and in HCV-RNA positive samples, genotyping was conducted. Results: A total of 114 patients who were seropositive for Anti HCV were recruited in the study, out of which 79 (69.29%) were HCV-RNA positive. Out of these positive samples, 54 were further subjected to genotype determination using real-time PCR. Genotype was not detected in 24 samples due to low viral load; 30 samples were positive for genotype. Conclusion: Knowledge of genotype is crucial for the management of HCV infection and prediction of prognosis. Patients infected with HCV genotype 1 and 4 will have to receive Interferon and Ribavirin for 48 weeks. Patients with these genotypes show a poor sustained viral response when tested 24 weeks after completion of therapy. On the contrary, patients infected with HCV genotype 2 and 3 are reported to have a better response to therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatocellular" title="hepatocellular">hepatocellular</a>, <a href="https://publications.waset.org/abstracts/search?q=genotype" title=" genotype"> genotype</a>, <a href="https://publications.waset.org/abstracts/search?q=ribavarin" title=" ribavarin"> ribavarin</a>, <a href="https://publications.waset.org/abstracts/search?q=seropositive" title=" seropositive"> seropositive</a> </p> <a href="https://publications.waset.org/abstracts/108722/detection-and-distribution-pattern-of-prevelant-genotypes-of-hepatitis-c-in-a-tertiary-care-hospital-of-western-india" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/108722.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">127</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1461</span> Uptake of Hepatitis B Vaccine among Hepatitis C Positive Patients and Their Vaccine Response in Myanmar</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Zaw%20Z%20Aung">Zaw Z Aung</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: High-risk groups for hepatitis B infection (HBV) are people who injected drugs (PWID), men who have sex with men (MSM), people living with HIV (PLHIV) and persons with hepatitis C (HCV), etc. HBV/HCV coinfected patients are at increased risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma. To the best of author’s knowledge, there is currently no data for hepatitis B vaccine utilization in HCV positive patients and their antibody response. Methodology: From February 2018 to May 2018, consented participants at or above 18 years who came to the clinic in Mandalay were tested with the anti-HCV rapid test. Those who tested HCV positive (n=168) were further tested with hepatitis B profile and asked about their previous hepatitis B vaccination history and risk factors. Results: Out of 168 HCV positive participants, three were excluded for active HBV infections. The remaining 165 were categorized into previously vaccinated 64% (n=106) and unvaccinated 36% (n=59) There were three characteristics groups- PWID monoinfected (n=77), General Population (GP) monoinfected (n=22) and HIV/HCV coinfected participants (n=66). Unvaccinated participants were highest in HIV/HCV, with 68%(n=45) followed by GP (23%, n=5) and PWID (12%, n=9). Among previously vaccinated participants, the highest percentage was PWID (88%, n=68), the second highest was GP (77%, n=17) and lowest in HIV/HCV patients (32%, n=21). 63 participants completed third doses of vaccination (PWID=36, GP=13, HIV/HCV=14). 53% of participants who completed 3 dose of hepatitis B were non-responders (n=34): HIV/HCV (86%, n=12), PWID (44%, n=16), and GP (46%, n=6) Conclusion: Even in the presence of effective and safe hepatitis B vaccine, uptake is low among high risk groups especially PLHIV that needs to be improved. Integration or collaboration of hepatitis B vaccination program, HIV/AIDS and hepatitis C treatment centers is desirable. About half of vaccinated participants were non-responders so that optimal doses, schedule and follow-up testing need to be addressed carefully for those groups. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20B%20vaccine" title="Hepatitis B vaccine">Hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C" title=" Hepatitis C"> Hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=HIV" title=" HIV"> HIV</a>, <a href="https://publications.waset.org/abstracts/search?q=Myanmar" title=" Myanmar"> Myanmar</a> </p> <a href="https://publications.waset.org/abstracts/97724/uptake-of-hepatitis-b-vaccine-among-hepatitis-c-positive-patients-and-their-vaccine-response-in-myanmar" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/97724.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">144</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1460</span> Low Volume High Intensity Interval Training Effect on Liver Enzymes in Chronic Hepatitis C Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Aya%20Gamal%20Khattab">Aya Gamal Khattab</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Chronic infection with the hepatitis C virus (HCV) is now the leading cause of liver-related morbidity and mortality; Currently, alanine aminotransferase ALT measurement is not only widely used in detecting the incidence, development, and prognosis of liver disease with obvious clinical symptoms, but also provides reference on screening the overall health status during health check-ups. Exercise is a low-cost, reliable and sustainable therapy for many chronic diseases. Low-volume high intensity interval training HIT is time efficient while also having wider application to different populations including people at risk for chronic inflammatory diseases. Purpose of this study was to investigate the effect of low volume high intensity interval training on ALT, AST in HCV patients. All practical work was done in outpatient physiotherapy clinic of Suez Canal Authority Hospitals. Forty patients both gender (27 male, 13 female), age ranged (40-60) years old submitted to low volume high intensity interval training on treadmill for two months three sessions per week. Each session consisting of five min warming up, two bouts for 10 min each bout consisting of 30 sec - 1 min of high intensity (75%-85%) HRmax then two to four min active recovery at intensity (40%-60%) HRmax, so the sum of high intensity intervals was one to two min for each session and four to eight min active recovery, and ends with five min cooling down. ALT and AST were measured before starting exercise session and 2 months later after finishing the total exercise sessions through blood samples. Results showed significant decrease in ALT, AST with improvement percentage (18.85%), (23.87%) in the study, so the study concluded that low volume high intensity interval training had a significant effect in lowering the level of circulating liver enzymes (ALT, AST) which means protection of hepatic cells and restoration of its function. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=alanine%20aminotransferase%20%28ALT%29" title="alanine aminotransferase (ALT)">alanine aminotransferase (ALT)</a>, <a href="https://publications.waset.org/abstracts/search?q=aspartate%20aminotransferase%20%28AST%29" title=" aspartate aminotransferase (AST)"> aspartate aminotransferase (AST)</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20C%20%28HCV%29" title=" hepatitis C (HCV)"> hepatitis C (HCV)</a>, <a href="https://publications.waset.org/abstracts/search?q=low%20volume%20high%20intensity%20interval%20training" title=" low volume high intensity interval training"> low volume high intensity interval training</a> </p> <a href="https://publications.waset.org/abstracts/42393/low-volume-high-intensity-interval-training-effect-on-liver-enzymes-in-chronic-hepatitis-c-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/42393.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">299</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1459</span> Epidemiology of Hepatitis B and Hepatitis C Viruses Among Pregnant Women at Queen Elizabeth Central Hospital, Malawi</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Charles%20Bijjah%20Nkhata">Charles Bijjah Nkhata</a>, <a href="https://publications.waset.org/abstracts/search?q=Memory%20Nekati%20Mvula"> Memory Nekati Mvula</a>, <a href="https://publications.waset.org/abstracts/search?q=Milton%20Masautso%20Kalongonda"> Milton Masautso Kalongonda</a>, <a href="https://publications.waset.org/abstracts/search?q=Martha%20Masamba"> Martha Masamba</a>, <a href="https://publications.waset.org/abstracts/search?q=Isaac%20Thom%20Shawa"> Isaac Thom Shawa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Viral Hepatitis is a serious public health concern globally with deaths estimated at 1.4 million annually due to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Hepatitis B and C are the most common viruses that cause liver damage. However, the majority of infected individuals are unaware of their serostatus. Viral Hepatitis has contributed to maternal and neonatal morbidity and mortality. There is no updated data on the Epidemiology of hepatitis B and C among pregnant mothers in Malawi. To assess the epidemiology of Hepatitis B and C viruses among pregnant women at Queen Elizabeth Central Hospital. Specific Objectives • To determine sero-prevalence of HBsAg and Anti-HCV in pregnant women at QECH. • To investigate risk factors associated with HBV and HCV infection in pregnant women. • To determine the distribution of HBsAg and Anti-HCV infection among pregnant women of different age group. A descriptive cross-sectional study was conducted among pregnant women at QECH in last quarter of 2021. Of the 114 pregnant women, 96 participants were consented and enrolled using a convenient sampling technique. 12 participants were dropped due to various reasons; therefore 84 completed the study. A semi-structured questionnaire was used to collect socio-demographic and behavior characteristics to assess the risk of exposure. Serum was processed from venous blood samples and tested for HBsAg and Anti-HCV markers utilizing Rapid screening assays for screening and Enzyme Linked Immunosorbent Assay for confirmatory. A total of 84 pregnant consenting pregnant women participated in the study, with 1.2% (n=1/84) testing positive for HBsAg and nobody had detectable anti-HCV antibodies. There was no significant link between HBV and HCV in any of the socio-demographic data or putative risk variables. The findings indicate a viral hepatitis prevalence lower than the set range by the WHO. This suggests that HBV and HCV are rare in pregnant women at QECH. Nevertheless, accessible screening for all pregnant women should be provided. The prevention of MTCT is key for reduction and prevention of the global burden of chronic viral Hepatitis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=viral%20hepatitis" title="viral hepatitis">viral hepatitis</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B" title=" hepatitis B"> hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20C" title=" hepatitis C"> hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=pregnancy" title=" pregnancy"> pregnancy</a>, <a href="https://publications.waset.org/abstracts/search?q=malawi" title=" malawi"> malawi</a>, <a href="https://publications.waset.org/abstracts/search?q=liver%20disease" title=" liver disease"> liver disease</a>, <a href="https://publications.waset.org/abstracts/search?q=mother%20to%20child%20transmission" title=" mother to child transmission"> mother to child transmission</a> </p> <a href="https://publications.waset.org/abstracts/146554/epidemiology-of-hepatitis-b-and-hepatitis-c-viruses-among-pregnant-women-at-queen-elizabeth-central-hospital-malawi" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/146554.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">169</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1458</span> Study of Circulatory MiR-122 and MiR-130a Expression among Chronic Hepatitis C Egyptian Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Hend%20K.%20Moosa">Hend K. Moosa</a>, <a href="https://publications.waset.org/abstracts/search?q=Eman%20A.%20Rashwan"> Eman A. Rashwan</a>, <a href="https://publications.waset.org/abstracts/search?q=Ezzat%20M.%20Hassan"> Ezzat M. Hassan</a>, <a href="https://publications.waset.org/abstracts/search?q=Amany%20A.%20Ghazy"> Amany A. Ghazy</a>, <a href="https://publications.waset.org/abstracts/search?q=Amel%20G.%20Sheredy"> Amel G. Sheredy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The stability of microRNA (miR) in the circulation can show a great progress toward the discovery of non-invasive diagnostic and prognostic biomarkers in many diseases. In the present study, circulatory miR-122 and miR-130a were analysed in chronic hepatitis C Egyptian patients in predicting the clinical outcome of interferon treatment. In addition, their expression levels were correlated to viral RNA levels, necro-inflammatory markers (AST, ALT) and to each other. This study was conducted on 51 subjects where 36 were chronic HCV patients in which they were divided into naive and interferon treated HCV patients (responders and non-responders) and 15 matched healthy controls. Serum quantification of miR-122 and miR-130a were performed by quantitative Real-time Polymerase Chain Reaction (qRT-PCR). The results showed a significant upregulation of miR-122 in non-responder patients (P=0.049). By receiver operating characteristic analysis curve, miR-122 revealed 65% sensitivity and 92.3% specificity in predicting non-responsiveness of patients to IFN treatment, while miR-130a showed a sensitivity of 100% and specificity of 53.85%. Remarkably, there was a significant positive correlation between miR-122 and miR-130a in naive HCV patients (r=0.714, p=0.003). However, there was no significant correlation between serum miR-122, miR-130a expression levels and necro-inflammatory markers (AST, ALT). To conclude, miR-122 and miR-130a have a significant association with viral RNA levels and accordingly, they may have a synergistic power in promoting viral replication. Interestingly, miR-122 and miR-130a have a predictive power in predicting clinical outcome of IFN treatment which can be further studied in currently used drugs in order to reduce the socio-economic burden of potentially non-responders. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20C" title="hepatitis C">hepatitis C</a>, <a href="https://publications.waset.org/abstracts/search?q=microRNA" title=" microRNA"> microRNA</a>, <a href="https://publications.waset.org/abstracts/search?q=miR-122" title=" miR-122"> miR-122</a>, <a href="https://publications.waset.org/abstracts/search?q=miR-130a" title=" miR-130a"> miR-130a</a> </p> <a href="https://publications.waset.org/abstracts/77630/study-of-circulatory-mir-122-and-mir-130a-expression-among-chronic-hepatitis-c-egyptian-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/77630.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">170</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1457</span> A Computer-Aided System for Detection and Classification of Liver Cirrhosis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abdel%20Hadi%20N.%20Ebraheim">Abdel Hadi N. Ebraheim</a>, <a href="https://publications.waset.org/abstracts/search?q=Eman%20Azomi"> Eman Azomi</a>, <a href="https://publications.waset.org/abstracts/search?q=Nefisa%20A.%20Fahmy"> Nefisa A. Fahmy</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This paper designs and implements a computer-aided system (CAS) to help detect and diagnose liver cirrhosis in patients with Chronic Hepatitis C. Our system reduces the required features (tests) the patient is asked to do to tests to their minimal best most informative subset of tests, with a diagnostic accuracy above 99%, and hence saving both time and costs. We use the Support Vector Machine (SVM) with cross-validation, a Multilayer Perceptron Neural Network (MLP), and a Generalized Regression Neural Network (GRNN) that employs a base of radial functions for functional approximation, as classifiers. Our system is tested on 199 subjects, of them 99 Chronic Hepatitis C.The subjects were selected from among the outpatient clinic in National Herpetology and Tropical Medicine Research Institute (NHTMRI). <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=liver%20cirrhosis" title="liver cirrhosis">liver cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=artificial%20neural%20network" title=" artificial neural network"> artificial neural network</a>, <a href="https://publications.waset.org/abstracts/search?q=support%20vector%20machine" title=" support vector machine"> support vector machine</a>, <a href="https://publications.waset.org/abstracts/search?q=multi-layer%20perceptron" title=" multi-layer perceptron"> multi-layer perceptron</a>, <a href="https://publications.waset.org/abstracts/search?q=classification" title=" classification"> classification</a>, <a href="https://publications.waset.org/abstracts/search?q=accuracy" title=" accuracy"> accuracy</a> </p> <a href="https://publications.waset.org/abstracts/39260/a-computer-aided-system-for-detection-and-classification-of-liver-cirrhosis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/39260.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">461</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1456</span> Effects of an Educational Program on Nurses Knowledge and Practice Related to Hepatitis-B: Pre-Experimental Design</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=R.%20S.%20Mehta">R. S. Mehta</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20N.%20Mandal"> G. N. Mandal </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Hepatitis-B is the major infectious disease of mankind. In Nepal it is reported that more than 4.3% of Nepalese population at any time in their life has been infected with Hepatitis-B virus (HBV). The objective of this study was to evaluate the effectiveness of planned educational programme regarding knowledge and practice of hepatitis-B among the nurses working at medical units of BPKIHS. Pre-experimental research design was used to conduct the study among the nurses working in medical units of BPKIHS. Total 40 nurses were included in the pre-test and 34 in the post-test. The education intervention was arranged on 24th May 2012 from 2:15 pm to 4:45 pm i.e. two and half hours. After two weeks of education intervention post-test was conducted. Most of the participants (60%) were of the age group of 18-22 years, Hindu (82.5%), and unmarried (65%). After education intervention there is significant differences in knowledge on the components of Hepatitis-B at 0.05 level of significance. There is no difference in the attitude components after post-test except the component patient contaminated with Hepatitis-B must be called as the last patient (p=0.035). It can conclude that hepatitis-B educational program improved knowledge and practice among the nurses. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=educational%20program" title="educational program">educational program</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis-B" title=" Hepatitis-B"> Hepatitis-B</a>, <a href="https://publications.waset.org/abstracts/search?q=pre-experimental%20design" title=" pre-experimental design"> pre-experimental design</a>, <a href="https://publications.waset.org/abstracts/search?q=medical%20units" title=" medical units "> medical units </a> </p> <a href="https://publications.waset.org/abstracts/16607/effects-of-an-educational-program-on-nurses-knowledge-and-practice-related-to-hepatitis-b-pre-experimental-design" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16607.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">356</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1455</span> Autoimmune Diseases Associated to Autoimmune Hepatitis: A Retrospective Study of 24 Tunisian Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Soumaya%20Mrabet">Soumaya Mrabet</a>, <a href="https://publications.waset.org/abstracts/search?q=Imen%20Akkari"> Imen Akkari</a>, <a href="https://publications.waset.org/abstracts/search?q=Amira%20Atig"> Amira Atig</a>, <a href="https://publications.waset.org/abstracts/search?q=Elhem%20Ben%20Jazia"> Elhem Ben Jazia</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease of unknown cause. Concomitant autoimmune disorders have been described in 30–50% of patients with AIH. The aim of our study is to determine the prevalence and the type of autoimmune disorders associated with AIH. Material and Methods: It is a retrospective study over a period of 16 years (2000-2015) including all patients followed for AIH. The diagnosis of AHI was based on the criteria of the revised International AIH group scoring system (IAIHG). Results: Twenty-for patients (21 women and 3 men) followed for AIH were collected. The mean age was 39 years (17-65 years). Among these patients, 11 patients(45.8%) had at least one autoimmune disease associated to AIH. These diseases were Hashimoto's thyroiditis (n = 5), Gougerot Sjogren syndrome (n=5), Primary biliary cirrhosis (n=2), Primitive sclerosant Cholangitis (n=1), Addison disease (n = 1) and systemic sclerosis (n=1). Patients were treated with corticosteroids alone or with azathioprine associated to the specific treatment of associated diseases with complete remission of AIH in 90% of cases and clinical improvement of other diseases. Conclusion: In our study, the prevalence of autoimmune diseases in AIH patients was 45.8%. These diseases were dominated by autoimmune thyroiditis and Gougerot Sjogren syndrome. The investigation of autoimmune diseases in autoimmune hepatitis must be systematic because of their frequency and the importance of adequate management. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=autoimmune%20diseases" title="autoimmune diseases">autoimmune diseases</a>, <a href="https://publications.waset.org/abstracts/search?q=autoimmune%20hepatitis" title=" autoimmune hepatitis"> autoimmune hepatitis</a>, <a href="https://publications.waset.org/abstracts/search?q=autoimmune%20thyroiditis" title=" autoimmune thyroiditis"> autoimmune thyroiditis</a>, <a href="https://publications.waset.org/abstracts/search?q=gougerot%20sjogren%20syndrome" title=" gougerot sjogren syndrome"> gougerot sjogren syndrome</a> </p> <a href="https://publications.waset.org/abstracts/66018/autoimmune-diseases-associated-to-autoimmune-hepatitis-a-retrospective-study-of-24-tunisian-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/66018.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">262</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1454</span> Detection of Bcl2 Polymorphism in Patient with Hepatocellular carcinoma </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Abdel-Hamid">Mohamed Abdel-Hamid</a>, <a href="https://publications.waset.org/abstracts/search?q=Olfat%20Gamil%20Shaker"> Olfat Gamil Shaker</a>, <a href="https://publications.waset.org/abstracts/search?q=Doha%20El-Sayed%20Ellakwa"> Doha El-Sayed Ellakwa</a>, <a href="https://publications.waset.org/abstracts/search?q=Eman%20Fathy%20Abdel-Maksoud"> Eman Fathy Abdel-Maksoud</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Despite advances in the knowledge of the molecular virology of hepatitis C virus (HCV), the mechanisms of hepatocellular injury in HCV infection are not completely understood. Hepatitis C viral infection (HCV) influences the susceptibility to apoptosis. This could lead to insufficient antiviral immune response and persistent viral infection. Aim of this study: was to examine whether BCL-2 gene polymorphism at codon 43 (+127G/A or Ala43Thr) has an impact on development of hepatocellular carcinoma caused by chronic hepatitis C Egyptian patients. Subjects and Methods: The study included three groups; group 1: composing of 30 patients with hepatocellular carcinoma (HCC), group 2 composing of 30 patients with HCV, group 3 composing of 30 healthy subjects matching the same age and socioeconomic status were taken as a control group. Gene polymorphism of BCL2 (Ala43Thr) were evaluated by PCR-RFLP technique and measured for all patients and controls. Results: The summed 43Thr genotype was more frequent and statistically significant in HCC patients as compared to control group. This genotype of BCL2 gene may inhibit the programmed cell death which leads to disturbance in tissue and cells homeostasis and reduction in immune regulation. This result leads to viral replication and HCV persistence. Moreover, virus produces variety of mechanisms to block genes participated in apoptosis. This mechanism proves that HCV patients who have 43Thr genotype are more susceptible to HCC. Conclusion: The data suggest for the first time that the BCL2 polymorphism is associated with the susceptibility to HCC in Egyptian populations and might be used as molecular markers for evaluating HCC risk. This study clearly demonstrated that Chronic HCV exhibit a deregulation of apoptosis with the disease progression. This provides an insight into the pathogenesis of chronic HCV infection, and may contribute to the therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=BCL2%20gene" title="BCL2 gene">BCL2 gene</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C%20Virus" title=" Hepatitis C Virus"> Hepatitis C Virus</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatocellular%20carcinoma" title=" Hepatocellular carcinoma"> Hepatocellular carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=sensitivity" title=" sensitivity"> sensitivity</a>, <a href="https://publications.waset.org/abstracts/search?q=specificity" title=" specificity"> specificity</a>, <a href="https://publications.waset.org/abstracts/search?q=apoptosis" title=" apoptosis"> apoptosis</a> </p> <a href="https://publications.waset.org/abstracts/18958/detection-of-bcl2-polymorphism-in-patient-with-hepatocellular-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/18958.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">508</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1453</span> Frequency of Hepatitis C Virus in Diagnosed Tuberculosis Cases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Farooq%20Baig">Muhammad Farooq Baig</a>, <a href="https://publications.waset.org/abstracts/search?q=Saleem%20Qadeer"> Saleem Qadeer</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The frequency of hepatitis C virus infection along with tuberculosis has not been widely investigated and very low statistics on rates of hepatitis C virus co-infection in tuberculosis patients. Hepatotoxicity is the major side effect of anti-tuberculosis therapy hepatitis HCVliver disease elevates the chances of hepatotoxicity up-to five folds. Objectives & Aim: To see the frequency of Hepatitis Cvirus infection amongst people with diagnosed Tuberculosis using gene X-pert technique. To evaluate the factors associated with HCVinfection in patients with MTBtuberculosis and to determine sensitivity and specificity of the tests. Study design: Comparative analytical study. Methodology: Three hundred and thirteen patients of tuberculosis diagnosed by Genexpert included while testing hepatitis C virus using immunochromotography rapid test technique, enzyme linked immunosorbent assay method and polymerase chain reaction test for confirmation. Results:Higher frequency of tuberculosis infection in males 57.8%, 42.5% between 20-39 years and 22% of hepatitis C virus infection in tuberculosis patients.The sensitivity of rapid test and enzyme-linked immunosorbent assay was 79% and 96% respectively while the specificity of rapid test and enzyme-linked immunosorbent assay was 91% and 99% respectively. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mycobactrium%20Tuberculosis" title="Mycobactrium Tuberculosis">Mycobactrium Tuberculosis</a>, <a href="https://publications.waset.org/abstracts/search?q=PC%27R" title=" PC'R"> PC'R</a>, <a href="https://publications.waset.org/abstracts/search?q=Gene%20x%20pert" title=" Gene x pert"> Gene x pert</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C%20virus" title=" Hepatitis C virus"> Hepatitis C virus</a> </p> <a href="https://publications.waset.org/abstracts/170292/frequency-of-hepatitis-c-virus-in-diagnosed-tuberculosis-cases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/170292.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">76</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1452</span> In Vitro Hepatoprotective and Anti-Hepatitis B Activitis of Cyperus rotundus Rhizome Fractions </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20K.%20Parvez">Mohammad K. Parvez</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmed%20H.%20Arbab"> Ahmed H. Arbab</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammed%20S.%20Al-Dosari"> Mohammed S. Al-Dosari </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cyperus rotendus rhizomes are used as traditional medicine, including Ayurveda in chronic liver diseases and hepatitis B. We investigated the in vitro hepatoprotective and anti-hepatitis B virus (HBV) potential of Cyperus rotundus rhizome organic and aqueous fractions. Of these, the n-butanol and aqueous fractions showed the most promising, dose-dependent hepatoprotection in DCFH-injured HepG2 cells at 48 h. DCFH-toxicated cells were recovered to about 88% and 96%, upon treatment with n-butanol and aqueous fractions (200 g/ml), respectively compared to DCFH-only treated cells. Further, C. rotundus fractions were tested for anti-HBV activities by measuring the expression levels of viral antigens (HBsAg and HBeAg) in the HepG2.2.15 culture supernatants. At 48 h post-treatment, the ethyl acetate, n-butanol and aqueous fractions showed dose-dependent inhibition wherein at a higher dose (100 g/ml), HBsAg production was reduced to 60.27%, 46.87 and 42.76%, respectively. In a time-course study, HBsAg production was inhibited up to 50% and 40% by ethyl acetate and n-butanol fractions (100 g/ml), respectively on day 5. Three three active fractions were further subjected to time-dependent inhibition of HBeAg expression, an indirect measure of HBV active DNA replication. At day 5 post-treatment, ethyl acetate and n-butanol fractions downregulated HBV replication by 44.14% and 24.70%, respectively. In conclusion, our results showed very promising hepatoprotective and anti-HBV potential of C. rotendus tubers fractions in vitro. Our data could, therefore, provide the basis for the claimed traditional use of C. rotendus for jaundice and hepatitis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anti-hepatitis%20B" title="anti-hepatitis B">anti-hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=cyperus%20rotundus" title=" cyperus rotundus"> cyperus rotundus</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20virus" title=" hepatitis B virus"> hepatitis B virus</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatoprotection" title=" hepatoprotection"> hepatoprotection</a> </p> <a href="https://publications.waset.org/abstracts/46692/in-vitro-hepatoprotective-and-anti-hepatitis-b-activitis-of-cyperus-rotundus-rhizome-fractions" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/46692.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">235</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1451</span> Lentiviral-Based Novel Bicistronic Therapeutic Vaccine against Chronic Hepatitis B Induces Robust Immune Response</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohamad%20F.%20Jamiluddin">Mohamad F. Jamiluddin</a>, <a href="https://publications.waset.org/abstracts/search?q=Emeline%20Sarry"> Emeline Sarry</a>, <a href="https://publications.waset.org/abstracts/search?q=Ana%20Bejanariu"> Ana Bejanariu</a>, <a href="https://publications.waset.org/abstracts/search?q=C%C3%A9cile%20Bauche"> Cécile Bauche </a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Over 360 million people are chronically infected with hepatitis B virus (HBV), of whom 1 million die each year from HBV-associated liver cirrhosis or hepatocellular carcinoma. Current treatment options for chronic hepatitis B depend on interferon-α (IFNα) or nucleos(t)ide analogs, which control virus replication but rarely eliminate the virus. Treatment with PEG-IFNα leads to a sustained antiviral response in only one third of patients. After withdrawal of the drugs, the rebound of viremia is observed in the majority of patients. Furthermore, the long-term treatment is subsequently associated with the appearance of drug resistant HBV strains that is often the cause of the therapy failure. Among the new therapeutic avenues being developed, therapeutic vaccine aimed at inducing immune responses similar to those found in resolvers is of growing interest. The high prevalence of chronic hepatitis B necessitates the design of better vaccination strategies capable of eliciting broad-spectrum of cell-mediated immunity(CMI) and humoral immune response that can control chronic hepatitis B. Induction of HBV-specific T cells and B cells by therapeutic vaccination may be an innovative strategy to overcome virus persistence. Lentiviral vectors developed and optimized by THERAVECTYS, due to their ability to transduce non-dividing cells, including dendritic cells, and induce CMI response, have demonstrated their effectiveness as vaccination tools. Method: To develop a HBV therapeutic vaccine that can induce a broad but specific immune response, we generated recombinant lentiviral vector carrying IRES(Internal Ribosome Entry Site)-containing bicistronic constructs which allow the coexpression of two vaccine products, namely HBV T- cell epitope vaccine and HBV virus like particle (VLP) vaccine. HBV T-cell epitope vaccine consists of immunodominant cluster of CD4 and CD8 epitopes with spacer in between them and epitopes are derived from HBV surface protein, HBV core, HBV X and polymerase. While HBV VLP vaccine is a HBV core protein based chimeric VLP with surface protein B-cell epitopes displayed. In order to evaluate the immunogenicity, mice were immunized with lentiviral constructs by intramuscular injection. The T cell and antibody immune responses of the two vaccine products were analyzed using IFN-γ ELISpot assay and ELISA respectively to quantify the adaptive response to HBV antigens. Results: Following a single administration in mice, lentiviral construct elicited robust antigen-specific IFN-γ responses to the encoded antigens. The HBV T- cell epitope vaccine demonstrated significantly higher T cell immunogenicity than HBV VLP vaccine. Importantly, we demonstrated by ELISA that antibodies are induced against both HBV surface protein and HBV core protein when mice injected with vaccine construct (p < 0.05). Conclusion: Our results highlight that THERAVECTYS lentiviral vectors may represent a powerful platform for immunization strategy against chronic hepatitis B. Our data suggests the likely importance of Lentiviral vector based novel bicistronic construct for further study, in combination with drugs or as standalone antigens, as a therapeutic lentiviral based HBV vaccines. THERAVECTYS bicistronic HBV vaccine will be further evaluated in animal efficacy studies. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B" title="chronic hepatitis B">chronic hepatitis B</a>, <a href="https://publications.waset.org/abstracts/search?q=lentiviral%20vectors" title=" lentiviral vectors"> lentiviral vectors</a>, <a href="https://publications.waset.org/abstracts/search?q=therapeutic%20vaccine" title=" therapeutic vaccine"> therapeutic vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=virus-like%20particle" title=" virus-like particle"> virus-like particle</a> </p> <a href="https://publications.waset.org/abstracts/34143/lentiviral-based-novel-bicistronic-therapeutic-vaccine-against-chronic-hepatitis-b-induces-robust-immune-response" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/34143.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">334</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1450</span> Association of Transmission Risk Factors Among HCV-infected Bangladeshi Patients With Different Genotypes</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nahida%20Sultana">Nahida Sultana</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year. The hepatitis C virus is a blood-borne virus, and most infections occur through exposure to blood from unsafe injection practices, unsafe health care, unscreened blood transfusion, injection drug use, and sexual practices that lead to exposure to blood. Hepatitis C virus (HCV) causes chronic infections that mainly affect the liver leading to liver diseases. This study aimed to determine whether there is any significant association between HCV transmission risk factors in relation to genotypes in HCV-infected Bangladeshi patients. After quantification of HCV viral load, 36 samples were randomly selected for HCV genotyping and risk factor measurement. A greater proportion of genotype 1 (p > 0.05) patients (40%) underwent blood transfusion compared to patients (22.6%) with genotype 3 infections. More genotype 1 patient underwent surgery and invasive procedures (20%), and rather than those with genotype 3 patients (16.1%). The history of IDUs (25.8%) and sexual exposure (3.2%) are only prevalent in genotype 3 patients and absent in patients with genotype 1 (p >0.05). There was no significant statistical difference found in HCV transmission risk factors (blood transfusion, IDUs, Surgery& interventions, sexual transmission) between patients infected with genotypes 1 and 3. In HCV infection, genotype may have no relation to transmission risk factors among Bangladeshi patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=HCV%20genotype" title="HCV genotype">HCV genotype</a>, <a href="https://publications.waset.org/abstracts/search?q=alanine%20aminotransferase%20%28ALT%29" title=" alanine aminotransferase (ALT)"> alanine aminotransferase (ALT)</a>, <a href="https://publications.waset.org/abstracts/search?q=HCV%20viral%20load" title=" HCV viral load"> HCV viral load</a>, <a href="https://publications.waset.org/abstracts/search?q=IDUs" title=" IDUs"> IDUs</a> </p> <a href="https://publications.waset.org/abstracts/157463/association-of-transmission-risk-factors-among-hcv-infected-bangladeshi-patients-with-different-genotypes" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/157463.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">86</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1449</span> A Medical Resource Forecasting Model for Emergency Room Patients with Acute Hepatitis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=R.%20J.%20Kuo">R. J. Kuo</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20C.%20Cheng"> W. C. Cheng</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20C.%20Lien"> W. C. Lien</a>, <a href="https://publications.waset.org/abstracts/search?q=T.%20J.%20Yang"> T. J. Yang</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Taiwan is a hyper endemic area for the Hepatitis B virus (HBV). The estimated total number of HBsAg carriers in the general population who are more than 20 years old is more than 3 million. Therefore, a case record review is conducted from January 2003 to June 2007 for all patients with a diagnosis of acute hepatitis who were admitted to the Emergency Department (ED) of a well-known teaching hospital. The cost for the use of medical resources is defined as the total medical fee. In this study, principal component analysis (PCA) is firstly employed to reduce the number of dimensions. Support vector regression (SVR) and artificial neural network (ANN) are then used to develop the forecasting model. A total of 117 patients meet the inclusion criteria. 61% patients involved in this study are hepatitis B related. The computational result shows that the proposed PCA-SVR model has superior performance than other compared algorithms. In conclusion, the Child-Pugh score and echogram can both be used to predict the cost of medical resources for patients with acute hepatitis in the ED. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20hepatitis" title="acute hepatitis">acute hepatitis</a>, <a href="https://publications.waset.org/abstracts/search?q=medical%20resource%20cost" title=" medical resource cost"> medical resource cost</a>, <a href="https://publications.waset.org/abstracts/search?q=artificial%20neural%20network" title=" artificial neural network"> artificial neural network</a>, <a href="https://publications.waset.org/abstracts/search?q=support%20vector%20regression" title=" support vector regression"> support vector regression</a> </p> <a href="https://publications.waset.org/abstracts/23255/a-medical-resource-forecasting-model-for-emergency-room-patients-with-acute-hepatitis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23255.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">422</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1448</span> Methylprednisolone Injection Did Not Inhibit Anti-Hbs Response Following Hepatitis B Vaccination in Mice</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=P.%20O.%20Ughachukwu">P. O. Ughachukwu</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20O.%20Okonkwo"> P. O. Okonkwo</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20C.%20Unekwe"> P. C. Unekwe</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20O.%20Ogamba"> J. O. Ogamba</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The prevalence of hepatitis B viral infection is high worldwide with liver cirrhosis and hepatocellular carcinoma as important complications. Cases of poor antibody response to hepatitis B vaccination abound. Immunosuppression, especially from glucocorticoids, is often cited as a cause of poor antibody response and there are documented evidences of irrational administration of glucocorticoids to children and adults. The study was, therefore, designed to find out if administration of glucocorticoids affects immune response to vaccination against hepatitis B in mice. Methods: Mice of both sexes were randomly divided into 2 groups. Daily intramuscular methylprednisolone injections, (15 mg kg-1), were given to the test group while sterile deionized water (0.1ml) was given to control mice for 30 days. On day 6 all mice were given 2 μg (0.1ml) hepatitis B vaccine and a booster dose on day 27. On day 34, blood samples were collected and analyzed for anti-HBs titres using enzyme-linked immunosorbent assay (ELISA). Statistical analysis was done using Graph Pad Prism 5.0 and the results taken as statistically significant at p value < 0.05. Results: There were positive serum anti-HBs responses in all mice groups but the differences in titres were not statistically significant. Conclusions: At the dosages and length of exposure used in this study, methylprednisolone injection did not significantly inhibit anti-HBs response in mice following immunization against hepatitis B virus. By extrapolation, methylprednisolone, when used in the usual clinical doses and duration of therapy, is not likely to inhibit immune response to hepatitis B vaccinations in man. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=anti-HBs" title="anti-HBs">anti-HBs</a>, <a href="https://publications.waset.org/abstracts/search?q=hepatitis%20B%20vaccine" title=" hepatitis B vaccine"> hepatitis B vaccine</a>, <a href="https://publications.waset.org/abstracts/search?q=immune%20response" title=" immune response"> immune response</a>, <a href="https://publications.waset.org/abstracts/search?q=methylprednisolone" title=" methylprednisolone"> methylprednisolone</a>, <a href="https://publications.waset.org/abstracts/search?q=mice" title=" mice"> mice</a> </p> <a href="https://publications.waset.org/abstracts/28711/methylprednisolone-injection-did-not-inhibit-anti-hbs-response-following-hepatitis-b-vaccination-in-mice" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/28711.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">323</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1447</span> An Investigation of Etiology of Liver Cirrhosis and Its Complications with Other Co-morbid Diseases</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tayba%20Akram">Tayba Akram</a> </p> <p class="card-text"><strong>Abstract:</strong></p> our main objective of this study is to work on the etiology of liver cirrhosis, to find basic reasons and causes of liver damage, and to find the pattern of liver cirrhosis in hepatic patients either suffering from hepatitis B/C or simple jaundice. We can evaluate medical treatment and the latest trends in patients suffering from liver cirrhosis. We can evaluate the side effects and adverse effects induced by drug therapy used to treat liver cirrhosis. The conclusion is based on the etiology of liver cirrhosis. The most common cause of liver cirrhosis is the viral Hepatitis C virus. Other common causes of liver cirrhosis that are estimated from our research are Hepatitis B virus, Diabetes Mellitus, Ascites, and very rarely found Hepatitis D virus. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=etiology" title="etiology">etiology</a>, <a href="https://publications.waset.org/abstracts/search?q=liver" title=" liver"> liver</a>, <a href="https://publications.waset.org/abstracts/search?q=cirrhosis" title=" cirrhosis"> cirrhosis</a>, <a href="https://publications.waset.org/abstracts/search?q=co-morbid%20diseases" title=" co-morbid diseases"> co-morbid diseases</a> </p> <a href="https://publications.waset.org/abstracts/193100/an-investigation-of-etiology-of-liver-cirrhosis-and-its-complications-with-other-co-morbid-diseases" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/193100.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">12</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">1446</span> An In-silico Pharmacophore-Based Anti-Viral Drug Development for Hepatitis C Virus</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Romasa%20Qasim">Romasa Qasim</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20M.%20Sayedur%20Rahman"> G. M. Sayedur Rahman</a>, <a href="https://publications.waset.org/abstracts/search?q=Nahid%20Hasan"> Nahid Hasan</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Shazzad%20Hosain"> M. Shazzad Hosain</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Millions of people worldwide suffer from Hepatitis C, one of the fatal diseases. Interferon (IFN) and ribavirin are the available treatments for patients with Hepatitis C, but these treatments have their own side-effects. Our research focused on the development of an orally taken small molecule drug targeting the proteins in Hepatitis C Virus (HCV), which has lesser side effects. Our current study aims to the Pharmacophore based drug development of a specific small molecule anti-viral drug for Hepatitis C Virus (HCV). Drug designing using lab experimentation is not only costly but also it takes a lot of time to conduct such experimentation. Instead in this in silico study, we have used computer-aided techniques to propose a Pharmacophore-based anti-viral drug specific for the protein domains of the polyprotein present in the Hepatitis C Virus. This study has used homology modeling and ab initio modeling for protein 3D structure generation followed by pocket identification in the proteins. Drug-able ligands for the pockets were designed using de novo drug design method. For ligand design, pocket geometry is taken into account. Out of several generated ligands, a new Pharmacophore is proposed, specific for each of the protein domains of HCV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=pharmacophore-based%20drug%20design" title="pharmacophore-based drug design">pharmacophore-based drug design</a>, <a href="https://publications.waset.org/abstracts/search?q=anti-viral%20drug" title=" anti-viral drug"> anti-viral drug</a>, <a href="https://publications.waset.org/abstracts/search?q=in-silico%20drug%20design" title=" in-silico drug design"> in-silico drug design</a>, <a href="https://publications.waset.org/abstracts/search?q=Hepatitis%20C%20virus%20%28HCV%29" title=" Hepatitis C virus (HCV)"> Hepatitis C virus (HCV)</a> </p> <a href="https://publications.waset.org/abstracts/64266/an-in-silico-pharmacophore-based-anti-viral-drug-development-for-hepatitis-c-virus" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/64266.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">271</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=49">49</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=50">50</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=chronic%20hepatitis%20B&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>